Galderma believes clinical trials are the most appropriate way for patients to access investigational medicines developed by Galderma. The safety and efficacy of investigational medicines are rigorously assessed by Galderma and the relevant regulatory agencies in order to understand the medicine’s benefits, risks, and appropriate use, including whether or not it should be approved as a therapy for its intended use. Obtaining regulatory approval is the best way to bring safe and effective medicines to the greatest number of patients who may benefit from treatment. Galderma is currently recruiting patients for multiple clinical trials. Click the links to learn more:
Nemolizumab
The study is to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments. (Two phase 3 links)
- Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis - Full Text View - ClinicalTrials.gov
- Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis - Full Text View - ClinicalTrials.gov
The study is to assess the efficacy of nemolizumab (CD14152) compared to placebo in participants greater than or equal to (>=) 18 years of age with prurigo nodularis (PN) after a 16 week treatment period.
- An Efficacy and Safety Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis - Full Text View - ClinicalTrials.gov
- A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN) - Full Text View - ClinicalTrials.gov
The study is to assess the pharmacokinetics (PK), efficacy, and safety of nemolizumab in pediatric participants with moderate-to-severe atopic dermatitis (AD).
Stay updated
Sign up for DermQuest Digest, our monthly update on news, science and trends in dermatology